Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms

International Journal of Clinical Practice

Volumn 67, Issue 12, 2013, Pages 1327-1333

  Jhang, J F ^a   Jiang, Y H ^a   Kuo, H C ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOXAZOSIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URINE FLOW RATE; URINE VOLUME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; BIOPSY; CYCLOOXYGENASE 2 INHIBITORS; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; URINATION;

EID: 84888071568     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12220     Document Type: Article

References (17)

1. Chung MS, Lee SH, Lee DH, et al. Practice patterns of korean urologists for screening and managing prostate cancer according to PSA Level. Yonsei Med J 2012; 53: 1136-41.
2. Berger AP, Gozzi C, Steiner H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 2004; 171: 1478-81.
3. Thompson IM, Chi C, Goodman PJ, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Nat Cancer Inst 2006; 98: 1128-33. (Pubitemid 44288787)
4. Serretta V, Catanese A, Daricello G, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis 2008; 11: 148-52. (Pubitemid 351676603)
5. Kandirali E, Boran C, Serin E, et al. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70: 743-7. (Pubitemid 350030236)
6. Soo Park D, Jin Oh J, Yup Hong J, et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study. Asian J Androl 2013; 15: 249-53.
7. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-84.
8. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 671-6.
9. Erol H, Beder N, Caliskan T, et al. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malignant prostatic pathologies? Urol Int 2006; 76: 20-6. (Pubitemid 43087516)
10. Ozdemir I, Bozkurt O, Demir O, et al. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009; 74: 431-5.
11. Kobayashi M, NuKui A, Morita T,. Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatits. Urol Int 2008; 80: 186-92. (Pubitemid 351440515)
12. Ugurlu O, Yaris M, Oztekin CV, et al. Impacts of antibiotic and anti-inflammatory therapies on serum prostatic inflammation: a prospective randomize control study. Urol Int 2010; 84: 185-90.
13. Chang SL, Harshman LC, Presti JC Jr,. Impact of common medication on serum prostate specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28: 3951-7.
14. Tubaro A, De Nuzio C, Mariani S, et al. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. Urology 2010; 76: 436-41.
15. Kim YJ, Kim SO, Ryu Kh, et al. Prostate cancer can be detected even in patients with decreased PSA less than 2.5 ng/ml after treatment to chronic prostatitis. Korean. J Urol 2011; 52: 457-60.
16. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-17.
17. Falahatkar S, Mokhtari G, Pourreza F, et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72: 813-6.